Salermide | CAS#1105698-15-4

Salermide
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407409

CAS#: 1105698-15-4

Description: Salermide is a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Salermide was well tolerated by mice at concentrations up to 100 muM and prompted tumour-specific cell death in a wide range of human cancer cell lines. The antitumour activity of Salermide was primarily because of a massive induction of apoptosis. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells.

Chemical Structure

Salermide

CAS# 1105698-15-4

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 407409
Name: Salermide
CAS#: 1105698-15-4
Chemical Formula: C26H22N2O2
Exact Mass: 394.17
Molecular Weight: 394.474
Elemental Analysis: C, 79.17; H, 5.62; N, 7.10; O, 8.11

Price and Availability

Size	Price	Availability
5mg	USD 350	2 weeks
10mg	USD 550	2 weeks
50mg	USD 1050	2 weeks
100mg	USD 1500	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Salermide

IUPAC/Chemical Name: N-[3-[[(2-hydroxy-1-naphthalenyl)methylene]amino]phenyl]-a-methyl-benzeneacetamide

InChi Key: HQSSEGBEYORUBY-WPWMEQJKSA-N

InChi Code: InChI=1S/C26H22N2O2/c1-18(19-8-3-2-4-9-19)26(30)28-22-12-7-11-21(16-22)27-17-24-23-13-6-5-10-20(23)14-15-25(24)29/h2-18,29H,1H3,(H,28,30)/b27-17+

SMILES Code: O=C(NC1=CC=CC(/N=C/C2=C3C=CC=CC3=CC=C2O)=C1)C(C)C4=CC=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Salermide is an inhibitor of SIRT1 and SIRT2, causing tumor-specific apoptotic cell death.
In vitro activity:	This study investigated the effects of HDAC inhibitors, including Salermide, on human pancreatic cancer cells (BxPC-3) alone and in combination with EF24 (EF). Salermide has potential in impacting pancreatic cancer cell behavior. Salermide significantly reduced the viability of BxPC-3 cells. Salermide and MS-275 treatments increased the acetylation of histone H3 and H4 and caused cell cycle arrest at the G1 phase. Reference: EXCLI J. 2016 Apr 4;15:246-55. https://pubmed.ncbi.nlm.nih.gov/27330528/
In vivo activity:	This study demonstrates that the combination of oxamflatin and salermide ameliorated duchenne muscular dystrophy mutant zebrafish skeletal muscle degeneration. The combination caused increased levels of histone H4 acetylation in zebrafish larvae. Reference: Skelet Muscle. 2020 Oct 15;10(1):29. https://pubmed.ncbi.nlm.nih.gov/33059738/

Preparing Stock Solutions

The following data is based on the product molecular weight 394.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Yar Saglam AS, Yilmaz A, Onen HI, Alp E, Kayhan H, Ekmekci A. HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells. EXCLI J. 2016 Apr 4;15:246-55. doi: 10.17179/excli2016-186. PMID: 27330528; PMCID: PMC4908665. 2. Dastjerdi MN, Salahshoor MR, Mardani M, Rabbani M, Hashemibeni B, Gharagozloo M, Kazemi M, Esmaeil N, Roshankhah Sh, Golmohammadi R, Mobarakian M. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PMID: 24019817; PMCID: PMC3764679. 3. Farr GH 3rd, Morris M, Gomez A, Pham T, Kilroy E, Parker EU, Said S, Henry C, Maves L. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Skelet Muscle. 2020 Oct 15;10(1):29. doi: 10.1186/s13395-020-00251-4. PMID: 33059738; PMCID: PMC7559456. 4. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, Varela-Rey M, Rotili D, Nebbioso A, Ropero S, Montoya G, Oyarzabal J, Velasco S, Serrano M, Witt M, Villar-Garea A, Imhof A, Mato JM, Esteller M, Fraga MF. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. doi: 10.1038/onc.2008.436. Epub 2008 Dec 8. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PMID: 19060927.
In vitro protocol:	1. Yar Saglam AS, Yilmaz A, Onen HI, Alp E, Kayhan H, Ekmekci A. HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells. EXCLI J. 2016 Apr 4;15:246-55. doi: 10.17179/excli2016-186. PMID: 27330528; PMCID: PMC4908665. 2. Dastjerdi MN, Salahshoor MR, Mardani M, Rabbani M, Hashemibeni B, Gharagozloo M, Kazemi M, Esmaeil N, Roshankhah Sh, Golmohammadi R, Mobarakian M. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PMID: 24019817; PMCID: PMC3764679.
In vivo protocol:	1. Farr GH 3rd, Morris M, Gomez A, Pham T, Kilroy E, Parker EU, Said S, Henry C, Maves L. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Skelet Muscle. 2020 Oct 15;10(1):29. doi: 10.1186/s13395-020-00251-4. PMID: 33059738; PMCID: PMC7559456. 2. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, Varela-Rey M, Rotili D, Nebbioso A, Ropero S, Montoya G, Oyarzabal J, Velasco S, Serrano M, Witt M, Villar-Garea A, Imhof A, Mato JM, Esteller M, Fraga MF. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. doi: 10.1038/onc.2008.436. Epub 2008 Dec 8. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PMID: 19060927.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Liu G, Su L, Hao X, Zhong N, Zhong D, Singhal S, Liu X. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012 Jul;16(7):1618-28. doi: 10.1111/j.1582-4934.2011.01401.x. PubMed PMID: 21801305; PubMed Central PMCID: PMC3823229.

2: Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, Varela-Rey M, Rotili D, Nebbioso A, Ropero S, Montoya G, Oyarzabal J, Velasco S, Serrano M, Witt M, Villar-Garea A, Imhof A, Mato JM, Esteller M, Fraga MF. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009 Feb 12;28(6):781-91. doi: 10.1038/onc.2008.436. Erratum in: Oncogene. 2009 Feb 26;28(8):1168. Inhof, A [corrected to Imhof, A]. PubMed PMID: 19060927.

3: Rotili D, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, Mellini P, Lenoci A, Pezzi R, Botta G, Lahtela-Kakkonen M, Poso A, Steinkühler C, Gallinari P, De Maria R, Fraga M, Esteller M, Altucci L, Mai A. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem. 2012 Dec 27;55(24):10937-47. doi: 10.1021/jm3011614. PubMed PMID: 23189967.

4: Salahshoor MR, Dastjerdi MN, Jalili C, Mardani M, Khazaei M, Darehdor AS, Valiani A, Roshankhah S. Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines. Int J Prev Med. 2013 Dec;4(12):1402-13. PubMed PMID: 24498496; PubMed Central PMCID: PMC3898446.

5: Yar Saglam AS, Yilmaz A, Onen HI, Alp E, Kayhan H, Ekmekci A. HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells. EXCLI J. 2016 Apr 4;15:246-55. doi: 10.17179/excli2016-186. PubMed PMID: 27330528; PubMed Central PMCID: PMC4908665.

6: Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010 Apr;9(4):844-55. doi: 10.1158/1535-7163.MCT-09-0971. PubMed PMID: 20371709.

7: Moretti NS, da Silva Augusto L, Clemente TM, Antunes RP, Yoshida N, Torrecilhas AC, Cano MI, Schenkman S. Characterization of Trypanosoma cruzi Sirtuins as Possible Drug Targets for Chagas Disease. Antimicrob Agents Chemother. 2015 Aug;59(8):4669-79. doi: 10.1128/AAC.04694-14. PubMed PMID: 26014945; PubMed Central PMCID: PMC4505258.

8: Dastjerdi MN, Salahshoor MR, Mardani M, Rabbani M, Hashemibeni B, Gharagozloo M, Kazemi M, Esmaeil N, Roshankhah Sh, Golmohammadi R, Mobarakian M. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci. 2013 Apr;8(2):79-89. PubMed PMID: 24019817; PubMed Central PMCID: PMC3764679.

9: Yao QP, Qi YX, Zhang P, Cheng BB, Yan ZQ, Jiang ZL. SIRT1 and Connexin40 Mediate the normal shear stress-induced inhibition of the proliferation of endothelial cells co-cultured with vascular smooth muscle cells. Cell Physiol Biochem. 2013;31(2-3):389-99. doi: 10.1159/000343376. PubMed PMID: 23548481.

10: Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, Liu T. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2013 Mar;20(3):503-14. doi: 10.1038/cdd.2012.147. PubMed PMID: 23175188; PubMed Central PMCID: PMC3569991.

11: Singh R, Yadav BS, Singh S, Pandey PN, Mani A. In-silico screening of Schistosoma mansoni Sirtuin1 inhibitors for prioritization of drug candidates. Springerplus. 2016 Mar 7;5:286. doi: 10.1186/s40064-016-1891-4. PubMed PMID: 27066323; PubMed Central PMCID: PMC4781818.

12: Lancelot J, Caby S, Dubois-Abdesselem F, Vanderstraete M, Trolet J, Oliveira G, Bracher F, Jung M, Pierce RJ. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2428. doi: 10.1371/journal.pntd.0002428. PubMed PMID: 24069483; PubMed Central PMCID: PMC3772001.

13: Takahashi S, Nakashima Y. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br J Nutr. 2012 Mar;107(6):774-80. doi: 10.1017/S0007114511003588. PubMed PMID: 21791144.

14: Park EY, Woo Y, Kim SJ, Kim DH, Lee EK, De U, Kim KS, Lee J, Jung JH, Ha KT, Choi WS, Kim IS, Lee BM, Yoon S, Moon HR, Kim HS. Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding. Int J Biol Sci. 2016 Dec 6;12(12):1555-1567. PubMed PMID: 27994519; PubMed Central PMCID: PMC5166496.

15: Kim TH, Kim HS, Kang YJ, Yoon S, Lee J, Choi WS, Jung JH, Kim HS. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts. Biochim Biophys Acta. 2015 Feb;1850(2):401-10. doi: 10.1016/j.bbagen.2014.11.007. PubMed PMID: 25445714.

16: Zhao Y, Luo P, Guo Q, Li S, Zhang L, Zhao M, Xu H, Yang Y, Poon W, Fei Z. Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo. Exp Neurol. 2012 Oct;237(2):489-98. doi: 10.1016/j.expneurol.2012.07.004. PubMed PMID: 22828134.

17: Villalba JM, Alcaín FJ. Sirtuin activators and inhibitors. Biofactors. 2012 Sep-Oct;38(5):349-59. doi: 10.1002/biof.1032. Review. PubMed PMID: 22730114; PubMed Central PMCID: PMC3467333.

Your view history

Salermide new featured